StreetInsider.com News Articles

Form 4 Lucid Diagnostics Inc. For: May 20 Filed by: Matheis Dennis

Thu, 21 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260521/26535718.html

Form 4 Lucid Diagnostics Inc. For: May 20 Filed by: Matheis Dennis

Thu, 21 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260521/26535718.html

Lucid Diagnostics Inc (LUCD) PT Lowered to $2 at Maxim Group

Fri, 15 May 2026 08:45:04 -0400

Maxim Group analyst Anthony Vendetti lowered the price target on Lucid Diagnostics Inc (NASDAQ: LUCD) to $2.00 (from $3.00) while maintaining a Buy rating.

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

Form 8-K Lucid Diagnostics Inc. For: May 14

Thu, 14 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26490419.html

Form 8-K Lucid Diagnostics Inc. For: May 14

Thu, 14 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26490419.html

Lucid Diagnostics Inc. (LUCD) Reports In-Line Q1 EPS

Thu, 14 May 2026 08:04:03 -0400

Lucid Diagnostics Inc. (NASDAQ: LUCD) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $1.38 million.

For earnings history and earnings-related data on Lucid Diagnostics Inc. (LUCD) click here.

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400

Processed 3,177 EsoGuard^® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones

Conference call and webcast to be held today, May 14, at 8:30 AM EDT

NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400

Conference call and webcast to be held today, May 14, at 8:30 AM EDT

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400

Conference call and webcast to be held today, May 14, at 8:30 AM EDT